(Total Views: 847)
Posted On: 11/13/2021 4:08:47 PM
Post# of 72440
Re: thefamilyman #70840
The real question is what is next for Brilacidin. The Phase 2 trial confirmed Brilacidin does not work for the severe to moderately ill covid patients.
Well, none of the other drugs did either eg Remdesivir, Regeneron's covid antibiotic,Ritonavir Molnupiravir,, or convalescent serum.
Did the other companies give up? No, they tried to find their niche in the treatment of covid. Do the other drugs have better in vitro results or a better safety profile than Brilacidin. In my opinion they do not.
Currently Pfizer's Ritonavir combination and Molnupiravir have to be given in 3-5 days to be effective as a means to prevent infection in high risk exposed patients.They are not approved for patients with active infections.
Regeneron's Covid antibiotic, casirivimab and imdevimab is used in high risk patients exposed to covid and those with mild to moderate out patient infections. The results are reasonably good.
https://investor.regeneron.com/news-releases/...levels-and
Brilacidin niche would be in the one now occupied by Regeneron.
It is possible Brilacidin could be safer and more effective, but that has to be confirmed in a clinical trail.
Is there a reason the Regeneron treatment for covid has not been approved?
IPIX's last PR mentioned the ACTIV 6 trial which is looking for anti covid activity in repurposed drugs.
The ACTIV6 currently is studying drugs including Ivermectin, Fluvoxamine and Fluticasone at 49 locations.
.The NIH is funding the study and is seeking additional drugs to study.
https://clinicaltrials.gov/ct2/show/NCT04885530
https://www.nih.gov/news-events/news-releases...9-symptoms
IPIX mentioned in their last PR the inclusion in the ACTIV trial is a goal.
"Complete analysis of trial results already has begun, with the aim to potentially identify positive trends in the data that could support Brilacidin for inclusion in larger COVID-19 platform trials, such as the U.K.’s CTAP program and the NIH’s ACTIV program. The purpose of these programs is to prioritize development of promising COVID-19 therapeutics"
Of course other possibilities for advancement of Brilacidin for Covid 19 exist. Further review of the Phase 2 study and compassionate use may result in the FDA approving a phase 3 study; especially in the setting of persistent Covid infections, the shortcomings of vaccinations. the poor results in treating patients with advanced covid and the probability additional mutations will develop.
Another possibility is combining Remdesivir and Brilacidin to take advantage of their synergistic antiviral effects.
GLTA, Farrell
.
Well, none of the other drugs did either eg Remdesivir, Regeneron's covid antibiotic,Ritonavir Molnupiravir,, or convalescent serum.
Did the other companies give up? No, they tried to find their niche in the treatment of covid. Do the other drugs have better in vitro results or a better safety profile than Brilacidin. In my opinion they do not.
Currently Pfizer's Ritonavir combination and Molnupiravir have to be given in 3-5 days to be effective as a means to prevent infection in high risk exposed patients.They are not approved for patients with active infections.
Regeneron's Covid antibiotic, casirivimab and imdevimab is used in high risk patients exposed to covid and those with mild to moderate out patient infections. The results are reasonably good.
https://investor.regeneron.com/news-releases/...levels-and
Brilacidin niche would be in the one now occupied by Regeneron.
It is possible Brilacidin could be safer and more effective, but that has to be confirmed in a clinical trail.
Is there a reason the Regeneron treatment for covid has not been approved?
IPIX's last PR mentioned the ACTIV 6 trial which is looking for anti covid activity in repurposed drugs.
The ACTIV6 currently is studying drugs including Ivermectin, Fluvoxamine and Fluticasone at 49 locations.
.The NIH is funding the study and is seeking additional drugs to study.
https://clinicaltrials.gov/ct2/show/NCT04885530
https://www.nih.gov/news-events/news-releases...9-symptoms
IPIX mentioned in their last PR the inclusion in the ACTIV trial is a goal.
"Complete analysis of trial results already has begun, with the aim to potentially identify positive trends in the data that could support Brilacidin for inclusion in larger COVID-19 platform trials, such as the U.K.’s CTAP program and the NIH’s ACTIV program. The purpose of these programs is to prioritize development of promising COVID-19 therapeutics"
Of course other possibilities for advancement of Brilacidin for Covid 19 exist. Further review of the Phase 2 study and compassionate use may result in the FDA approving a phase 3 study; especially in the setting of persistent Covid infections, the shortcomings of vaccinations. the poor results in treating patients with advanced covid and the probability additional mutations will develop.
Another possibility is combining Remdesivir and Brilacidin to take advantage of their synergistic antiviral effects.
GLTA, Farrell
.
(9)
(0)Scroll down for more posts ▼
